Jim Simons's position in Allogene Therapeutics is currently worth $4.56M. That's 0.01% of their equity portfolio (1423rd largest holding). The investor owns 1.12% of the outstanding Allogene Therapeutics stock. The first Allogene Therapeutics trade was made in Q2 2020. Since then Jim Simons bought shares ten more times and sold shares on eleven occasions. The investor's estimated purchase price is $10.1M, resulting in a loss of 55%.